Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,226 recruiting studies in this area right now.
By phase
- Not applicable9,543
- Phase 24,410
- Phase 12,677
- Phase 1/Phase 21,654
- Phase 31,397
- Phase 2/Phase 3284
- Phase 4261
Top conditions
- Breast Cancer1,200
- Prostate Cancer645
- Cancer635
- Colorectal Cancer480
- Lung Cancer418
- Ovarian Cancer338
- Multiple Myeloma330
- Pancreatic Cancer290
- Gastric Cancer281
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma256
- Solid Tumor246
- Advanced Solid Tumor232
- Head and Neck Cancer226
- Cervical Cancer225
- Endometrial Cancer210
- Advanced Solid Tumors203
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center291
- Sun Yat-sen University275
- Mayo Clinic238
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences143
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,414
- Texas634
- Arizona507
- Florida437
- Alabama428
- New York406
- Massachusetts342
- Maryland329
- New Jersey273
- Pennsylvania232
Recruiting studies20,226 total
- NCT07374848RecruitingPhase 1
Study of ZL-6201 for sarcoma and some solid tumors
This trial tests a new drug called ZL-6201 for people with sarcoma or certain solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and helps shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07378969Recruiting
Study on T-cell cancers after tisagenlecleucel treatment
This study looks at people who developed a new T-cell cancer after receiving the CAR-T therapy tisagenlecleucel (Kymriah). Researchers want to understand these rare cancers by testing stored tumor samples. You may be eligible if you had tisagenlecleucel and were later diagnosed with a T-cell malignancy.
Kurume, FukuokaAges 15–15 - NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07377045RecruitingPhase 1
New combo for advanced pancreatic cancer
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT07375355Recruiting
A study of Scemblix for newly diagnosed chronic myeloid leukemia in China
This study looks at how well the medicine Scemblix (asciminib) works for people in China who have just been diagnosed with a certain type of leukemia (chronic myeloid leukemia in chronic phase). It aims to see if starting this treatment soon after diagnosis is effective and safe.
Wuhan, HubeiAges 18–99 - NCT07372625RecruitingPhase 1
How rezatapopt affects common drugs in advanced solid tumors with TP53 Y220C mutation
This trial tests how rezatapopt changes the way your body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C gene change. It helps doctors understand the right dose for future patients.
Denver, ColoradoAges 18 years+ - NCT07378098RecruitingPhase 3
Study of KLH-2109 for uterine fibroids with heavy bleeding
This trial tests a new medicine called KLH-2109 for women who have uterine fibroids that cause heavy menstrual bleeding. The goal is to see if the medicine can reduce bleeding and improve symptoms.
SeoulAges 19 years+ - NCT07376642RecruitingEarly Phase 1
Testing IMV101 for relapsed B-cell lymphoma
This study tests an experimental drug called IMV101 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to other treatments. It aims to see if the drug is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07376629Enrolling by invitationPhase 2
Study of HB0025 plus nab-paclitaxel for first-line TNBC
This trial tests a new drug (HB0025) combined with chemotherapy (nab-paclitaxel) as the first treatment for people with triple-negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard care.
AnyangAges 18–75 - NCT07377578RecruitingPhase 3
Rocbrutinib vs other BTK inhibitors for mantle cell lymphoma
This study tests a new targeted therapy called Rocbrutinib against other BTK inhibitors for people with mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see which works better and how safe they are.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07377487Recruiting
TheraSphere for liver cancer before market in Japan
This trial tests a treatment called TheraSphere for people with liver cancer that hasn't responded to standard care or can't have it. TheraSphere uses tiny radioactive beads to target tumors in the liver, and this study is being done to get it approved in Japan.
Nishinomiya, HyōgoAges 18 years+ - NCT07371104RecruitingPhase 1
Study of DWZ2501 in advanced BRCA ovarian cancer on olaparib
This trial compares how the body processes a new formulation of olaparib (DWZ2501) versus the standard version. It is for women with advanced, BRCA-mutated high-grade ovarian cancer who are already on or about to start a stable dose of olaparib 300 mg twice daily.
Seoul, Jongno-guAges 19 years+ - NCT06841653Recruiting
AI model to predict risk and improve treatment for endometrial cancer
This trial is testing whether a computer model powered by artificial intelligence can better predict outcomes for people with endometrial cancer or related conditions. It uses patient data and tissue samples to see if the model can help doctors choose the best care.
RomeAges 18 years+ - NCT06651866RecruitingPhase 1
Study of D-CMG for older adults with new AML
This trial tests a new drug combination called D-CMG for people aged 60–75 who have just been diagnosed with a type of leukemia (AML) and cannot have standard chemotherapy. The goal is to find a safe and effective dose.
Xiamen, FujianAges 60–75 - NCT06737523RecruitingPhase 1
A new combination therapy for relapsed or refractory AML
This trial tests a three-drug combination for patients whose AML has returned or not responded to prior treatment. It aims to see if adding a new drug (Chiglitazar) to standard treatments (Venetoclax and Azacitidine) can help control the leukemia.
Xiamen, FujianAges 18 years+ - NCT06670911RecruitingPhase 2
Lower dose pembrolizumab with chemo for advanced cervical cancer
This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Rio de Janeiro, Rio de JaneiroAges 18 years+ - NCT06766526Recruiting
Online support for emotional adjustment after prostate cancer
This trial tests an online support program to help men cope with emotional distress after prostate cancer. You participate from home using a computer or smartphone.
LinköpingAges 18 years+ - NCT06788639Recruiting
Long-term study of Breyanzi for CLL/SLL in real-world care
This study looks at people with CLL or SLL who have already been treated with the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in routine medical care. It collects information about how well the treatment works and how patients are doing over time, without giving any new treatment.
Milwaukee, WisconsinAges 18 years+ - NCT06794268Recruiting
Long-term health study for people with lymphoma treated with liso-cel
This study looks at patients with a type of lymphoma (follicular lymphoma) who have already received a CAR T-cell therapy called liso-cel. Researchers want to track their health over time and see how well the treatment works and how safe it is in routine medical care.
Milwaukee, WisconsinAges 18 years+ - NCT06841484Recruiting
Robotic tools vs. human-assisted tools in stomach cancer surgery
This study tests two ways of using robotic tools during stomach cancer surgery: one where the surgeon controls all instruments from a console, and another where a human assistant operates some tools. It aims to see which method works better for patients having the lower part of the stomach removed.
SeoulAges 20 years+ - NCT04271644RecruitingPhase 1/Phase 2
CAR-T treatment targeting BCMA for hard-to-treat myeloma
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
Kunming, YunnanAges 18–75 - NCT04016675Recruiting
Radiation before surgery for cancer of the tear sac
This trial studies giving radiation before surgery for malignant (cancerous) tumors of the tear sac. It may help shrink the tumor and improve how well treatment works when surgery is planned.
ShanghaiAges 18–80 - NCT04903678Recruiting
Chemo into spinal fluid for advanced retinoblastoma spread
This trial studies giving chemotherapy directly into the spinal fluid to treat retinoblastoma that has spread to the central nervous system (brain/spinal cord). It may help by targeting tumor cells that are in the fluid around the brain and spinal cord.
ShanghaiAges Any age - NCT02674100Recruiting
Registry for pancreatic cancer patients getting a specific ablation
This is a research registry that collects information from adults with pancreatic cancer who are treated with an ablation procedure called irreversible electroporation (IRE). It may help doctors better understand which patients benefit from this approach and how the treatment is used in real life.
Birmingham, AlabamaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,226 recruiting oncology studies from the U.S. registry right now, out of 30,453 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.